Medivir AB Release: Simeprevir Has Been Approved In Canada As A New Treatment For Hepatitis C
Published: Nov 20, 2013
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that Health Canada has approved simeprevir for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with ribavirin.
Help employers find you! Check out all the jobs and post your resume.